Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 67-kDa laminin receptor (67LR) is a high-affinity, non-integrin cell-surface receptor that plays a critical role in cell-matrix interactions by binding to the laminin extracellular matrix protein, specifically recognizing the YIGSR (Tyr-Ile-Gly-Ser-Arg) peptide sequence of the laminin beta-1 chain. Derived from the dimerization of a 37-kDa cytosolic precursor (37LRP) encoded by the RPSA gene, 67LR is a multifunctional protein that also functions as a ribosomal component involved in translation and nuclear structure maintenance. In oncology, 67LR is frequently overexpressed in various cancers, where its expression levels correlate with increased tumor aggressiveness, cell migration, invasion, angiogenesis, and metastasis. Additionally, 67LR serves as a cell-surface receptor for several pathogens, including viruses (such as Sindbis and dengue) and cellular prion proteins, facilitating their entry and internalization. Therapeutic targeting of 67LR has focused on small-molecule inhibitors like NSC47924 to block laminin binding and prevent metastatic spread, as well as agonists like epigallocatechin gallate (EGCG) that bind 67LR to trigger cancer-specific apoptotic pathways. However, because of its dual role in essential ribosomal translation, targeting 67LR presents significant safety challenges regarding potential toxicity to normal cellular metabolism.
Inhibition of laminin binding to 67LR to block cell adhesion, migration, and invasion; or activation of 67LR-mediated apoptotic signaling (e.g., via EGCG) to induce cancer cell death.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 67-kDa laminin receptor (67LR).